Closing the Gap: Ensuring Access to and Quality of Contraceptive Implant Removal Services is Essential to Rights-based Contraceptive Care

Rebecca Howett, Alida M Gertz, Tiroyaone Kgaswanyane, Gregory Petro, Lesego Mokganya, Sifelani Malima, Tshego Maotwe, Melanie Pleaner, Chelsea Morroni

Abstract

The use of the subdermal contraceptive implant is increasing globally, and particularly so in lower- and middle-income countries in sub-Saharan Africa. For initiation or discontinuation of the implant, users need to have access to services for insertion and removal by healthcare providers. Providing access to safe and effective contraceptive implant removal services presents both clinical and programmatic challenges. The most challenging implant removal cases, termed ―difficult removals‖, place additional demands upon removal services. In this commentary, we outline challenges for the provision of removal services. Based on our experience in this field, we make recommendations on how healthcare providers and health services can plan for these challenges. Through maximising the provision of comprehensive and accessible implant removal services, including those for difficult removals, implant users can be empowered to discontinue their use of this method of contraception if they choose, thus upholding the principles of rights-based contraceptive care. (Afr J Reprod Health 2019; 23[4]: 19-26).

Full Text:

PDF

References

Jacobstein R. Liftoff: the blossoming of contraceptive implant use in Africa. Glob Health Sci Pract

;6(1):17-39.

Polis CB, Bradley SEK, Bankole A, Onda T, Croft T and Singh S. Contraceptive failure rates in the developing world: an analysis of demographic and health survey data in 43 countries. New York: Guttmacher Institute; 2016, http://www.guttmacher.org/report/contraceptive failure-rates-developing-world-analysisdemographic-and-health-survey-data-43 [accessed

July 2019].

Trussell J and Aiken ARA. Contraceptive efficacy. In: Hatcher RA, et al. Contraceptive Technology, 21st

revised edition. New York, NY: Ardent Media; 2018.

Ross J and Stover J. Use of modern contraception increases when more methods become available:

analysis of evidence from 1982–2009. Glob Health Sci and Pract. 2013;1(2):203-212.

World Health Organisation. Medical eligibility criteria for contraceptive use 5th ed. Geneva: WHO; 2015.

Merck. Merck announces extension of access pricing for contraceptive implants Implanon

® and Implanon NXT® in family planning 2020 countries, http://ec2-54-210-230-186.compute-1.amazonaws.com/wpcontent/uploads/2015/11/IMPLANON-Pricing

Announcement-003.pdf [accessed 11 May 2019].

Bayer. Choices in secure long-term contraception, http://pharma.bayer.com/en/commitment

responsibility/family-planning/implant-initiative/ [accessed 11 May 2019].

Duvall S, Thurston S, Weinberger M, Nuccio O and Fuchs-Montgomery N. Scaling up delivery of

contraceptive implants in sub-Saharan Africa: operational experiences of Marie Stopes International. Glob Health Sci Pract. 2014;2(1):72- 92.

EngenderHealth. Voluntary family planning programs that respect, protect and fulfill human rights: a

conceptual framework, https://www.engenderhealth.org/wpcontent/uploads/imports/files/pubs/family

planning/human-rights-based-family planning/Voluntary_Family_Planning_Programs_A_Conceptual_Framework.pdf [accessed 11 May 2019].

United Nations. Transforming our world: the 2030 agenda for sustainable development, https://sustainabledevelopment.un.org/content/documents/21252030%20Agenda%20for%20Sustainable %20Development%20web.pdf [accessed 11 May 2019].

World Health Organization. Quality of care in contraceptive information and services, based on

human rights standards: A checklist for health care providers. Geneva: WHO; 2017.

United Nations Population Fund. Programme of action:adopted at the International Conference on Population and Development, Cairo, 5-13 September 1994, https://www.unfpa.org/sites/default/files/pubpdf/programme_of_action_Web%20ENGLISH.pdf

[accessed 11 May 2019].

Cottingham J, Germain A and Hunt P. Use of human rights to meet the unmet need for family planning.

Lancet 2012; 380:172-180.

Pillay D, Chersich MF, Morroni C, Pleaner M, Adeagbo OA, Naidoo N, Mullick S and Rees H. User

perspectives on Implanon NXT in South Africa: a survey of 12 public-sector facilities. S Afr Med J

;107(10):815-821.

Pleaner M, Morroni C, Smit J, Lince-Deroche N, Chersich MF, Mullick S, Pillay D, Makua M and

Rees H. Lessons learnt from the introduction of the contraceptive implant in South Africa. S Afr Med J

;107(11):933-938.

World Health Organization. WHO recommendations: optimizing health worker roles to improve access to

key maternal and newborn health interventions through task shifting. Geneva: WHO; 2012,

http://apps.who.int/iris/ bitstream/10665/77764/1/9789241504843_eng.pdf

[accessed 29 July 2019].

Mascarenhas L. Insertion and removal of Implanon® . Contraception 1998; 58:79S–83S.

Mansour D, Mommers E, Teede H, Sollie-Eriksen B, Graesslin O, Ahrendt HJ and Gemzell-Danielsson K.

Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an

open-label, noncontrolled, multicenter trial. Contraception 2010;82(3):243-249.

Mansour D, Walling M, Glenn D, Egarter C, Graesslin O, Herbst J and Fraser IS. Removal of non-palpable

etonogestrel implants. J Fam Plann Reprod Health Care 2008;34(2):89-91.

Mansour D. UK provision for removal of nonpalpable contraceptive implants. J Fam Plann Reprod Health Care 2009;35(1):3-4.

Iwanga J, Fox MC, Rekers H, Schwartz L and Tubbs RS. Neurovascular anatomy of the adult female medial

arm in relationship to potential sites for insertion of thee tonogestrel contraceptive implant.

Contraception 2019;100(1):26-30.

Darney P, Patel A, Rosen K, Shapiro L and Kaunitz A. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91(5):1646-1653.

Dunson TR, Amatya RN and Krueger SL. Complications and risk factors associated with the removal of

Norplant implants. Obstet Gynecol 1995; 85:543- 548.

Chevreau J, Krief D, Abou Arab O, Zitoun M, Foulon A, Sergent F and Gondry J. Factors associated with

removal difficulties of etonogestrel-containing contraceptive implants (Nexplanon® ). Eur J Obstet

Gynecol Reprod Biol 2018; 224:81-84.

Belvea C, Ernat J and Gumboc R. Removal of a contraceptive implant from the brachial neurovascular sheath. J Hand Surg Am 2017;42(2): e115-e117.

Agrawal A and Robinson C. Spontaneous snapping of an Implanon in two halves in situ. J Fam Plann Reprod

Health Care 2003;29(4):238.

Torres R, Mendes N, Machado AI and Marques C. In situ breakage of Implanon

® – two cases of a rare occurrence. Contraception 2013;88(1):189-191.

Bentley J. Experience and removal of damaged implants. J Fam Plann Reprod Health Care 2013; 39:233-234.

Park JU, Bae HS, Lee SM, Bae J and Park JW. Removal of a subdermal contraceptive implant (Implanon

NXT) that migrated to the axilla by C-arm guidance: A case report and review of the literature. Medicine

(Baltimore) 2017;96(48): e8627.

Vidin E, Garbin O, Rodriguez B, Favre R and BettaharLebugle K. Removal of etonogestrel contraceptive

implants in the operating theater: report on 28 cases. Contraception 2007;76(1):35-39.

Nouri K, Pinker-Domenig K, Ott J, Fraser I and Egarter C. Removal of non-palpable Implanon

® with the aid of a hook-wire marker. Contraception 2013;88(4):577-580.

Chen MJ and Creinin MD. Removal of a nonpalpable etonogestrel implant with preprocedure

ultrasonography and modified vasectomy clamp. Obstet Gynecol 2015;126(5):935-938.

Singh M, Mansour D and Richardson D. Location and removal of non-palpable Implanon

® implants with the aid of ultrasound guidance. J Fam Plann Reprod Health Care 2006;32(3):154-156.

Petro GA. Non-palpable and difficult contraceptive implant removals: The New Somerset Hospital

referral-clinic experience. S Afr J Obstet Gynaecol 2017;23(3):101-104.

Kang W and Hian Tan K. A simple technique for localisation of deeply inserted, non-palpable

Norplant implant. Contraception 2005;71(5):392-394.

Merki-Feld GS, Brekenfield C, Migge B and Keller PJ. Nonpalpable ultrasonographically not detectable Implanon rods can be localised by magnetic resonance imaging. Contraception 2001;63(6):325- 328.

Guiahi M, Tocce K, Teal S, Green T and Rochon P. Removal of a Nexplanon® implant located in the biceps muscle using a combination of ultrasound and fluoroscopy guidance. Contraception 2014;90(6):606-608.

Mansour D, Fraser IS, Walling M, Glenn D, Graesslin O, Egarter C and Herbst J. Methods of accurate

localisation of non-palpable subdermal contraceptive implants. J Fam Plann Reprod Health Care

;34(1):9-12.

Christofield M and Lacoste M. Accessible contraceptive implant removal services: an essential element of

quality service delivery and scale-up. Glob Health Sci Pract. 2016;4(3):366-372.

Sergison JE, Stalter RM, Callahan RL, Rademacher KH and Steiner MK. Cost of contraceptive implant removal services must be considered when responding to the growing demand for removals. Glob Health Sci Pract. 2017;5(2):330-332.

EngenderHealth. Contraceptive hormonal implant removal services: experiences from the ExpandFP Project in the Democratic Republic of the Congo, Tanzania, and Uganda, https://www.engenderhealth.org/files/pubs/project/expandfp/Expand-FPbrief_implant_removals_final.pdf [accessed 11 May 2019].

Nageso A and Gebretsadik A. Discontinuation rate of Implanon and its associated factors among women who ever used Implanon in Dale District, Southern Ethiopia. BMC Womens Health. 2018;18(1):189.

Teunissen AM, Grimm B and Roumen FJ. Continuation rates of the subdermal contraceptive Implanon

® and associated influencing factors. Eur J Contracept Reprod Health Care 2014;19(1):15-21.

Weisberg E, Bateson D, McGeechan K and Mohapatra L. A three-year comparative study of continuation

rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or

progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care 2014;19(1):5-14.

Pillay D, Morroni C, Pleaner M, Adeagdo OA, Chersich MF, Naidoo N, Mullick S and Rees H. Gaps in monitoring systems for Implant NXT services in South Africa: an assessment of 12 facilities in two districts. S Afr Med J 2017;107(10):827-831.

United Nations Population Fund. Botswana introduces contraceptive implants, http://botswana.unfpa.org/news/botswana introduces-contraceptive-implants [accessed 11 May 2019].

Adeagbo OA, Mullick S, Pillay D, Chersich MF, Morroni C, Naidoo N, Pleaner M and Rees H. Uptake and early removals of Implanon NXT in South Africa: perceptions and attitudes of healthcare workers. S Afr Med J 2017;107(10):822-826.

Sivin I, Nash H and Waldman S. Jadelle® levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience. New York, NY: Population Council; 2002.

Kumar, J. How does quality of care relate to a rightsbased approach to family planning programs?

http://www.popcouncil.org/uploads/pdfs/2015RH_Q OC-RightsBasedFP_wp1.pdf [accessed 11 May

.

Refbacks

  • There are currently no refbacks.